MX2013010025A - (-)-huperzina a procesos y composiciones relacionadas y métodos de tratamiento. - Google Patents

(-)-huperzina a procesos y composiciones relacionadas y métodos de tratamiento.

Info

Publication number
MX2013010025A
MX2013010025A MX2013010025A MX2013010025A MX2013010025A MX 2013010025 A MX2013010025 A MX 2013010025A MX 2013010025 A MX2013010025 A MX 2013010025A MX 2013010025 A MX2013010025 A MX 2013010025A MX 2013010025 A MX2013010025 A MX 2013010025A
Authority
MX
Mexico
Prior art keywords
huperzine
pure
processes
methods
treatment
Prior art date
Application number
MX2013010025A
Other languages
English (en)
Other versions
MX346339B (es
Inventor
Seth Herzon
Maung Kyaw Moe Tun
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of MX2013010025A publication Critical patent/MX2013010025A/es
Publication of MX346339B publication Critical patent/MX346339B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)

Abstract

La invención proporciona (1) procesos para producir (-) -huperzina A prácticamente pura y derivados de (-) -huperzina A prácticamente puros; (2) composiciones útiles en la producción de (-) -huperzina A prácticamente pura y derivados de (-) -huperzina A prácticamente puros; y (3) métodos de tratamiento o prevención de trastornos neurológicos que utilizan (-) -huperzina A prácticamente pura y derivados de (-) -huperzina A prácticamente puros.
MX2013010025A 2011-03-04 2012-02-17 (-)-huperzina a procesos y composiciones relacionadas y métodos de tratamiento. MX346339B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161449198P 2011-03-04 2011-03-04
PCT/US2012/025628 WO2012121863A1 (en) 2011-03-04 2012-02-17 (--)- huperzine a processes and related compositions and methods of treatment

Publications (2)

Publication Number Publication Date
MX2013010025A true MX2013010025A (es) 2014-03-27
MX346339B MX346339B (es) 2017-03-15

Family

ID=46798513

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010025A MX346339B (es) 2011-03-04 2012-02-17 (-)-huperzina a procesos y composiciones relacionadas y métodos de tratamiento.

Country Status (11)

Country Link
US (5) US10059672B2 (es)
EP (2) EP3434669B1 (es)
JP (2) JP5922157B2 (es)
KR (1) KR102017123B1 (es)
CN (2) CN103687849B (es)
AU (2) AU2012226251B2 (es)
CA (1) CA2829026C (es)
ES (2) ES2847229T3 (es)
MX (1) MX346339B (es)
PL (2) PL2681199T3 (es)
WO (1) WO2012121863A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10287249B2 (en) 2014-10-03 2019-05-14 Amphastar Pharmaceuticals, Inc. Methods of resolving racemic mixture to obtain (−)-huperzine A
WO2018213838A1 (en) * 2017-05-19 2018-11-22 Biscayne Neurotherapeutics, Inc. Modified release pharmaceutical compositions of huperzine and methods of using the same
CN109200051A (zh) * 2017-07-03 2019-01-15 南京和博生物医药有限公司 石杉碱甲及其类似物作为治疗炎症性疾病药物的用途
CN114702391A (zh) * 2021-12-17 2022-07-05 青岛科技大学 一种利用双氧水进行霍夫曼重排制环丙胺的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5104880A (en) * 1991-05-01 1992-04-14 Mayo Foundation For Medical Education And Research Huperzine a analogs as acetylcholinesterase inhibitors
USRE38460E1 (en) 1994-12-28 2004-03-09 Shanghai Institute Of Materia Medica Chinese Academy Of Sciences Huperzine A derivatives, their preparation and their use
CN1052225C (zh) * 1994-12-28 2000-05-10 中国科学院上海药物研究所 石杉碱甲衍生物,其制备方法和用途
JPH0995483A (ja) * 1995-07-27 1997-04-08 Sagami Chem Res Center （１１Ｅ）−５−アミノ−１１−エチリデン−５，６，９，１０−テトラヒドロ−７−メチル−５，９−メタノシクロオクタ［ｂ］ピリジン−２（１Ｈ）−オン誘導体およびその製造中間体
JPH1036352A (ja) * 1996-07-23 1998-02-10 Sagami Chem Res Center （１１Ｅ）−５−アミノ−１１−エチリデン−５，６，９，１０−テトラヒドロ−５，９−メタノシクロオクタ［ｂ］ピリジン−２（１Ｈ）−オン誘導体およびその製造中間体
WO1999011625A1 (en) * 1997-09-03 1999-03-11 Macro Hi-Tech Jv, Ltd. Huperzine a derivatives
US6271397B1 (en) 1998-06-05 2001-08-07 Showa Denko Kabushiki Kaisha L-ascorbic acid-2-phosphoric acid potassium crystal and method for producing the same
US6271379B1 (en) * 2000-03-08 2001-08-07 Georgetown University Intermediates useful for the synthesis of huperzine A
IL152848A0 (en) 2000-06-12 2003-06-24 Eisai Co Ltd 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof
US8193212B2 (en) 2005-05-23 2012-06-05 President And Fellows Of Harvard College Use of huperzine for neuropathic pain
CN101130520B (zh) * 2006-08-24 2010-05-12 中国科学院上海药物研究所 经非对映异构体盐的外消旋体拆分制备天然(-)-石杉碱甲和非天然(+)-石杉碱甲的新方法
CN100528844C (zh) * 2007-04-20 2009-08-19 中国科学院昆明植物研究所 石杉碱甲衍生物,其制备方法和其应用
WO2009120774A2 (en) * 2008-03-25 2009-10-01 Debiopharm S.A. Method of preparing huperzine a and derivatives thereof

Also Published As

Publication number Publication date
JP2014508777A (ja) 2014-04-10
CN103687849B (zh) 2016-08-17
US20180237395A1 (en) 2018-08-23
PL3434669T3 (pl) 2021-05-31
US20200392086A1 (en) 2020-12-17
AU2012226251B2 (en) 2017-05-04
US20200109118A1 (en) 2020-04-09
KR102017123B1 (ko) 2019-09-02
US10059672B2 (en) 2018-08-28
JP2016185949A (ja) 2016-10-27
US10457643B2 (en) 2019-10-29
CA2829026C (en) 2020-08-11
US10781179B2 (en) 2020-09-22
AU2017204748B2 (en) 2019-06-20
ES2701730T3 (es) 2019-02-25
CN106117140A (zh) 2016-11-16
US20220064123A1 (en) 2022-03-03
AU2017204748A1 (en) 2017-07-27
JP5922157B2 (ja) 2016-05-24
AU2012226251A1 (en) 2013-10-17
PL2681199T3 (pl) 2019-03-29
WO2012121863A1 (en) 2012-09-13
CN106117140B (zh) 2020-05-05
CA2829026A1 (en) 2012-09-13
US11142503B2 (en) 2021-10-12
US20150158817A1 (en) 2015-06-11
EP2681199A1 (en) 2014-01-08
EP2681199A4 (en) 2014-08-06
EP3434669A1 (en) 2019-01-30
JP6200996B2 (ja) 2017-09-20
EP2681199B1 (en) 2018-09-26
CN103687849A (zh) 2014-03-26
MX346339B (es) 2017-03-15
EP3434669B1 (en) 2020-11-04
KR20140009444A (ko) 2014-01-22
ES2847229T3 (es) 2021-08-02

Similar Documents

Publication Publication Date Title
WO2013169704A3 (en) TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
EP4324527A3 (en) Formulations of enzalutamide
MX2018004832A (es) Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
WO2011022489A3 (en) (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
MY165728A (en) Selective glycosidase inhibitors and uses thereof
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
MX2010002312A (es) Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
JO3819B1 (ar) H1- بيرازولو [4، 3-b] بيريدينات كمثبطات PDE1
MX2015001250A (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
WO2007098122A3 (en) Methods for the treatment of macular degeneration and related eye conditions
IN2012DN02624A (es)
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
WO2010121225A3 (en) Method of treating disorders associated with protein kinase ck2 activity
MY150600A (en) Use of opioid antagonists for treating urinary retention
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX346339B (es) (-)-huperzina a procesos y composiciones relacionadas y métodos de tratamiento.
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
WO2010065861A3 (en) Inhibitors of bace 1 and methods for treating alzheimer's disease
HK1141436A1 (en) Axomadol for treating pain from arthritis

Legal Events

Date Code Title Description
FG Grant or registration